Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aclidinium
Drug ID BADD_D02465
Description Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Indications and Usage Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB08897
KEGG ID Not Available
MeSH ID Not Available
PubChem ID 11434515
TTD Drug ID D0VP1V
NDC Product Code Not Available
UNII K17VY42F6C
Synonyms Not Available
Chemical Information
Molecular Formula C26H30NO4S2+
CAS Registry Number 727649-81-2
SMILES C1C[N+]2(CCC1C(C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.0120.001476%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000434%Not Available
Arrhythmia02.03.02.0010.000955%Not Available
Asthma10.01.03.010; 22.03.01.0020.004861%Not Available
Bronchospasm22.03.01.004; 10.01.03.0120.001823%
Bronchospasm paradoxical22.03.01.0060.000434%Not Available
Cardiac failure02.05.01.001--
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000955%Not Available
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.0020.000651%Not Available
Chronic obstructive pulmonary disease22.03.01.0070.009853%Not Available
Condition aggravated08.01.03.0040.001910%Not Available
Confusional state19.13.01.001; 17.02.03.0050.003169%
Cough22.02.03.0010.003689%
Deafness04.02.01.0010.000434%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.005295%
Drug ineffective08.06.01.006--Not Available
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.0010.005165%
Dysphonia19.19.03.002; 17.02.08.004; 22.12.03.0060.002431%
Dyspnoea02.11.05.003; 22.02.01.0040.046573%
Dyspnoea exertional02.11.05.005; 22.02.01.0050.001172%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.000434%
Eye pain06.08.03.0020.000955%
Feeling abnormal08.01.09.0140.000434%Not Available
Glossodynia07.14.02.0010.000955%Not Available
Hypersensitivity10.01.03.0030.001302%
Hypertension24.08.02.0010.002214%
Hyperventilation22.02.01.006; 19.01.02.0040.000955%Not Available
Hypoxia22.02.02.0030.000434%
Joint swelling15.01.02.0040.000955%Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages